Skip to Main Content

Paper Details

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.
Clin Cancer Res
92
2019
BRAF, BRAF-mutant gliomas, DNA, DNA repair dysfunctions, ERK, Gliomas, IDH, IDH mutation, MEK, RAF, astrocytomas, enhancing tumors, glioma, gliomas, heritable genetic syndromes, patients, tumor, tumors
Author NameAffiliation
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Marc LadanyiMemorial Sloan Kettering Cancer Center
Marc LadanyiMemorial Sloan Kettering Cancer Center
Thomas J KaleyMemorial Sloan Kettering Cancer Center
Thomas J KaleyMemorial Sloan Kettering Cancer Center
Mariza DarasMemorial Sloan Kettering Cancer Center
Mariza DarasMemorial Sloan Kettering Cancer Center
Mariza DarasMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanMemorial Sloan Kettering Cancer Center
Cameron BrennanMemorial Sloan Kettering Cancer Center
Cameron BrennanMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
  • 1 - 21

Datasets